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Background
Increased secretion of growth hormone leads to gigantism in children and acro-
megaly in adults; the genetic causes of gigantism and acromegaly are poorly under-
stood.
Methods
We performed clinical and genetic studies of samples obtained from 43 patients 
with gigantism and then sequenced an implicated gene in samples from 248 pa-
tients with acromegaly.
Results
We observed microduplication on chromosome Xq26.3 in samples from 13 patients 
with gigantism; of these samples, 4 were obtained from members of two unrelated 
kindreds, and 9 were from patients with sporadic cases. All the patients had disease 
onset during early childhood. Of the patients with gigantism who did not carry an 
Xq26.3 microduplication, none presented before the age of 5 years. Genomic char-
acterization of the Xq26.3 region suggests that the microduplications are generated 
during chromosome replication and that they contain four protein-coding genes. 
Only one of these genes, GPR101, which encodes a G-protein–coupled receptor, was 
overexpressed in patients’ pituitary lesions. We identified a recurrent GPR101 mutation 
(p.E308D) in 11 of 248 patients with acromegaly, with the mutation found mostly 
in tumors. When the mutation was transfected into rat GH3 cells, it led to increased 
release of growth hormone and proliferation of growth hormone–producing cells.
Conclusions
We describe a pediatric disorder (which we have termed X-linked acrogigantism 
[X-LAG]) that is caused by an Xq26.3 genomic duplication and is characterized by 
early-onset gigantism resulting from an excess of growth hormone. Duplication 
of GPR101 probably causes X-LAG. We also found a recurrent mutation in GPR101 in 
some adults with acromegaly. (Funded by the Eunice Kennedy Shriver National 
Institute of Child Health and Human Development and others.)
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Somatic growth is orchestrated by a complex hormonal crosstalk involving the hypothalamus, pituitary, and peripheral tis-
sues.1 Genetic disorders that affect this network 
can lead to increased secretion of growth hor-
mone, which results in acromegaly. If the excess 
in growth hormone occurs before epiphyseal fu-
sion, the result can be gigantism. Nonsyndromic 
gigantism is most frequently caused by pituitary 
adenomas occurring as familial isolated pituitary 
adenomas or sporadically, usually as a result of 
mutations in the gene encoding aryl hydrocarbon 
receptor–interacting protein (AIP).2-4 Other mono-
genic diseases can cause gigantism, but most of 
these conditions develop in adulthood in associa-
tion with other tumors.5 In young children, so-
matic overgrowth that is due to an excess of 
growth hormone is rare, and the cause is un-
known. Other syndromic genetic overgrowth con-
ditions in children, such as the Sotos syndrome 
and the Simpson–Golabi–Behmel syndrome, are 
not associated with pituitary abnormalities.6,7
We report a striking phenotype of gigantism 
that has an onset in early childhood and that is 
caused by an excess of growth hormone. The 
disorder is associated with heritable microdupli-
cations on chromosome Xq26.3. There are four 
genes in the duplicated stretch of DNA; one of 
these, GPR101, encodes an orphan G-protein–
coupled receptor and is probably the gene that 
drives the phenotype in young children and the 
growth of sporadic growth hormone–producing 
adenomas in some patients with acromegaly.
Me thods
Patients
We analyzed samples obtained from 43 patients 
with gigantism who had hypersecretion of 
growth hormone, evidence of an anterior pitu-
itary lesion on magnetic resonance imaging, a 
height on country-specific growth charts of ei-
ther more than the 97th percentile or more than 
2 SD above the mean height for age, and negative 
test results for mutations or deletions in genes 
associated with pituitary adenomas (Table 1). 
Details with respect to one family with this syn-
drome8,9 and two patients with sporadic dis-
ease10,11 have been described previously.
Genetic Analyses
We sequenced the four genes in the duplicated 
region on chromosome Xq26.3 in 259 germline 
and tumor DNA samples that were obtained 
from 248 patients with sporadic acromegaly (Ta-
ble S1 in the Supplementary Appendix, available 
with the full text of this article at NEJM.org). We 
sequenced GPR101 and performed array compar-
ative genomic hybridization (aCGH) on germline 
DNA in samples obtained from 13 families with 
familial isolated pituitary adenomas without AIP 
mutations. We used quantitative reverse-transcrip-
tase–polymerase-chain-reaction (qRT-PCR) assays 
to measure the expression levels of duplicated 
genes in both leukocytes and pituitary tumors. 
We performed comparative protein-structure 
modeling on GPR101 using Modeller software, 
version 9.13.12 We determined the level of growth 
hormone and cyclic AMP (cAMP) and the rate of 
cellular proliferation after transient overexpres-
sion of each of the four implicated genes in GH3 
cells obtained from rat pituitary tumors.
Study Oversight
The institutional review board at each of the par-
ticipating institutions approved our studies. We 
studied the anonymized samples from interna-
tional acromegaly cohorts with approval from the 
National Institutes of Health Intramural Office 
for Human Research Protections. Written in-
formed consent was obtained from all adult pa-




The clinical and biochemical characteristics of 
the 43 patients who had nonsyndromic gigan-
tism without abnormalities in genes associated 
with pituitary tumors are presented in Table 1. 
Genetic analyses delineated two phenotypes: an 
early-childhood form of gigantism with a typical 
onset in late infancy (Fig. 1) and a second form 
with a typical onset in adolescence.
Identification of Xq26.3 Microduplication
We detected microduplications on chromosome 
Xq26.3 in samples obtained from patients with 
the early-childhood form of gigantism (Fig. 2, 
and Fig. S1, S2, and S3 in the Supplementary Ap-
pendix). Nine of the 13 patients with an Xq26.3 
microduplication and the 1 probable carrier (an 
affected mother with gigantism) were female 
and were of normal size at birth. All the patients 
grew rapidly during infancy, attaining a median 
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height score of +3.8 SD at diagnosis (median age, 
36 months). At the time of diagnosis, they 
showed marked overall somatic growth, with el-
evated weight and an enlarged head circumfer-
ence (median, 51.2 cm). The onset of accelerated 
growth and the onset of accelerated weight gain 
usually coincided but were not always synchro-
nous (Fig. 1, and Fig. S4 in the Supplementary 
Appendix). As compared with patients who did 
not have an Xq26.3 microduplication, those with 
the microduplication had an earlier median age 
at the onset of abnormal growth (12 months vs. 
16 years), an increased acceleration in height, 
and elevated levels of insulin-like growth factor 1 
and prolactin (Table 1). We did not observe pre-
cocious puberty in the microduplication carriers. 
Levels of peripheral growth hormone–releasing 
hormone did not suggest ectopic secretion of this 
hormone, and nuclear imaging scans were nega-
tive for other tumors.
Of the 13 patients who underwent surgery, 10 
had pituitary macroadenomas alone (median 
maximum diameter, 16 mm), and 3 patients had 
pituitary hyperplasia, with or without an identi-
fied adenoma (Fig. 3H). In all the patients, hor-
monal control was not achieved with medical 
therapy alone. Such control required either radi-
cal or repeated neurosurgery alone (in 4 pa-
tients) or in combination with the administra-
tion of the growth hormone receptor antagonist 
pegvisomant (in 3 patients) or radiotherapy (in 
2 patients). Seven patients had permanent hypo-
pituitarism at the time of this study.
The common duplicated genomic segment 
was approximately 500 kb in length, from posi-
tion 135,627,637 to 136,118,269 (GRCh37/hg19) 








Female sex — no. (%) 10 (71) 7 (24)  0.007
Median age at onset of rapid growth (range) — yr 1.0 (0.5 to 2.0) 16.0 (5.0 to 18.0) <0.001
Median age at diagnosis (range) — yr 3 (1 to 22) 21 (5 to 34) <0.001
Median height at diagnosis (range) — cm 116 (99 to 175) 187 (171 to 209) <0.001
Median standard-deviation score for height at 
diagnosis (range)
+3.8 (+1.9 to +7.1) +3.3 (+2.1 to +5.8) 0.45
Elevated levels of growth hormone and insulin-like 
growth factor 1 at diagnosis — no. (%)
14 (100) 29 (100) 1.00
No suppression of growth hormone during oral 
glucose-tolerance test — no. (%)
14 (100) 29 (100) 1.00
Median factor increase in insulin-like growth factor 1 
at diagnosis (range) — multiple of ULN
4.4 (2.4 to 5.2) 2.1 (1.4 to 5.3)  0.005
Elevated prolactin level at diagnosis — no. (%) 13 (93) 6 (21) <0.001
Median maximum tumor diameter (range) — cm 16 (10 to 39) 20 (9 to 41) 0.16
Adenoma or hyperplasia — no. (%)†
Both adenoma and hyperplasia 2 (14) 0
Adenoma only 10 (71) 29 (100) —
Hyperplasia only 1 (7) 0
Type of syndrome — no. (%)
Sporadic 9 (64) 29 (100) —
Familial  5 (36)‡ 0
Siblings with normal growth — no./total no. (%) 9/11 (82) 29/29 (100) —
* ULN denotes upper limit of the normal range.
† The presence of hyperplasia or adenoma could not be determined in one patient who did not undergo surgery.
‡ In one patient with the familial syndrome, pituitary gigantism was diagnosed in the mother and son at the same visit, 
when the son was 8 years of age and the mother was 22 years of age. The mother had had tall stature and acromegalic 
features since childhood for which she had not been referred for medical attention. The clinical data for the mother, for 
whom DNA was not available, are included.
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(Fig. 2). One patient had a complex genomic re-
arrangement, with two duplicated segments that 
were separated by a short region of normal ge-
nomic sequence. No other patterns of duplica-
tion or deletion or homozygosity were shared 
among the affected patients. One family with 
familial isolated pituitary adenomas included an 
affected mother and two affected sons (who 
have been described previously 8) with the same 
Xq26.3 microduplication; the unaffected father 
did not have the duplication. In another family 
with this condition, the mother had childhood-
onset gigantism and a histologically confirmed 
pituitary macroadenoma but had died of com-
plications of hypopituitarism. She had two 
children: the son carried the Xq26.3 microdu-
plication and had childhood-onset gigantism 
(Patient F2A), and the healthy daughter did not 
have the duplication. The most parsimonious ex-
planation is that the son inherited the X-linked 
disease from his carrier mother. Hence, Xq26.3 
microduplications can be considered to be a 
new pathogenic explanation in certain kindreds 
with familial isolated pituitary adenomas that 































Figure 2. Summary of the Genomic Gains on Chromosome Xq26.3.
Shown are 10 different Xq26.3 microduplications, as seen on array comparative genomic hybridization, that were 
found in 12 patients with familial or sporadic gigantism (with the inheritance pattern indicated at right). Duplicated 
genomic segments (red) and nonduplicated segments (white) are shown. The genomic coordinates are provided at 
base-pair resolution on the x axis. The two smallest regions of overlap (SRO), SRO1 and SRO2, are identified, show-
ing the genomic contents in the corresponding regions. The symbols next to the gene names represent the struc-
ture of the genes, with vertical lines representing exons and horizontal lines (with or without arrows) representing 
introns. Adapted from the UCSC Genes track in the UCSC Genome Browser.
Figure 1 (facing page). Familial and Sporadic Cases  
of Gigantism and Male and Female Growth Patterns 
Due to the Xq26.3 Microduplications.
Panel A shows Patient F1C, who has familial gigantism, 
at the age of 3 years. His growth chart up to 24 months 
of age shows the rapid acceleration in weight, although 
the acceleration in height did not begin until after his 
second birthday (Fig. S4 in the Supplementary Appendix). 
Panel B shows an unaffected mother and her daughter 
(Patient S6), who has sporadic gigantism and whose 
height was 120 cm at the age of 3 years. A growth chart 
for Patient S4 (Panel C), another girl with sporadic gigan-
tism, illustrates the typical early increase in height and 
weight seen in patients with Xq26.3 microduplications, 
starting at the age of 6 months in this child.
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Further Characterization of Xq26.3 
Microduplication
Using high-definition analysis of the critical du-
plicated region, we analyzed 10 distinct genomic 
duplications in 12 patients, including 4 patients 
with the familial form of the disease and 8 pa-
tients with the sporadic form (Fig. S1 and S3 in 
the Supplementary Appendix). On genomewide 
aCGH, these mutations appeared to be simple 
duplications. However, using high-resolution 
aCGH, long-range PCR, and Sanger sequencing 
of the breakpoints, we found various underlying 
genomic complexities (Fig. S3 in the Supplemen-
tary Appendix).
All sporadic Xq26.3 duplications were nonre-
current; the boundaries of the duplicated seg-
ment were unique to each patient. On both 
aCGH and breakpoint PCR assays, samples ob-
tained from unaffected parents and siblings of 
patients with sporadic disease showed negative 
results, documenting the microduplication as a 
new mutation (Fig. S3A and S5A in the Supple-
mentary Appendix). The same duplication was 
transmitted from an affected mother (Patient F1A) 
to her affected offspring, Patients F1B and F1C 
(Fig. 2, and Fig. S3 and S5B in the Supplemen-
tary Appendix).
The duplicated genomic regions that were 
shared by all affected persons consisted of the 
two smallest regions of overlap (SRO), which were 
designated as SRO1 and SRO2 (Fig. 2). SRO1 
(chromosomal position, 135,627,637 to 135,986,830; 
hg19) encompassed three genes in the Online 
Mendelian Inheritance in Man (OMIM) data-
base: CD40LG (OMIM number, 300386), ARHGEF6 
(OMIM number, 300267), and RBMX (OMIM 
number, 300199), whereas SRO2 (chromosomal 
position, 136,045,310 to 136,118,269; hg19) in-
cluded GPR101 (OMIM number, 300393) (Fig. 2).
Investigation of Candidate Genes
Sequencing of each of the four genes in the 43 
patients with gigantism did not reveal any single-
nucleotide variants of likely pathogenicity. A 
quantitative RT-PCR assay of pituitary tumor 
RNA from 2 patients with Xq26.3 microduplica-
tions suggested that CD40LG was not expressed in 
the pituitary tumors. Neither ARHGEF6 nor RBMX 
showed up-regulated expression in the pituitary 
tumors of 2 patients with the duplication (Fig. 4). 
In contrast, the expression of GPR101 in the pitu-
itaries of the children carrying an Xq26.3 dupli-
cation was increased by a factor as high as 1000, 
as compared with unaffected pituitary tissue and 
pituitary tumors from persons who tested nega-
tive for microduplications (Fig. 4A). This result 
was confirmed at the protein level by increased 
immunostaining for GPR101 in pituitary tumors 
from patients with Xq26.3 duplications (Fig. 3G, 
and Fig. S7 in the Supplementary Appendix). Ex-
perimental overexpression of ARHGEF6, RBMX, 
and GPR101 alone in the rat GH3 cell line did not 
significantly increase either cell proliferation or 
the secretion of growth hormone (Fig. 4D and 
4E, and Fig. S8 in the Supplementary Appendix). 
Nonmutated GPR101 in combination with ARH-
GEF6, RBMX, or both modestly increased cell pro-
liferation but not the secretion of growth hor-
mone (Fig. S8 in the Supplementary Appendix).
The X-chromosome–inactivation pattern was 
random in the female patients with sporadic 
disease and skewed in Patient F1A, who had fa-
milial disease; CpG islands were identified in 
silico only in RBMX and GPR101 (Fig. S9 and S10 
in the Supplementary Appendix).
Identification of p.E308D Mutation in GPR101
In a series of 248 patients with sporadic acro-
megaly, none carried a microduplication at 
Xq26.3. However, 11 patients had a c.924G→C 
substitution (p.E308D) in GPR101, which was not 
found in 7600 control samples obtained from 
public databases (Tables S1 and S2 in the Supple-
mentary Appendix). Of the 11 mutation carriers, 
3 appeared to carry a constitutive mutation, 
which was detected in DNA from peripheral-
blood mononuclear cells (PBMCs). We detected 
the mutation in the tumor DNA in the remaining 
8 patients (Fig. 5A). In one patient, we deter-
mined that the mutation was a de novo somatic 
mutation — that is, the GPR101 mutation oc-
curred only in the tumor DNA sequence and not 
in the PBMC sequence (Fig. 5B). None of the 13 
families with familial isolated pituitary adeno-
mas carried the p.E308D mutation in GPR101.
GPR101 encodes an orphan G-protein–coupled 
receptor that is highly expressed in rodent hypo-
thalamus (Fig. S11 and S12 in the Supplemen-
tary Appendix) and is predicted to couple to the 
stimulatory G protein (Gs), a potent activator of 
adenylyl cyclase.13,14 A model of human GPR101 
in complex with a Gs heterotrimer shows the phy-
sical relationship between the p.E308D amino 
acid change and the activating p.A397K change, 
a mutation that has been described previously.15 
The two amino acids, which are predicted to be 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
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Figure 5. Effect of the p.E308D Mutation in GPR101 in 11 Patients with Sporadic Acromegaly.
Panel A shows the sequence for GPR101 in growth hormone–producing pituitary tumors obtained from patients with 
sporadic acromegaly, as compared with normal tissue. Panel B shows results for a patient with a somatic mutation, 
which was determined by the presence of the mutation in the GPR101 sequence of DNA in the tumor sample but 
not in the sequence in peripheral-blood mononuclear cells. None of the 13 families with familial isolated pituitary 
adenomas carried the p.E308D mutation in GPR101. Panel C shows a structural model of GPR101 bearing the p.E308D 
mutation. Residue A397 is located at the cytosolic end of transmembrane (TM) 6 of GPR101. The mutated D308 res-
idue and the nonmutated A397 residue are shown in space-filling representation and colored according to elements, 
with carbon atoms in gray, oxygen atoms in red, and nitrogen atoms in blue. The backbone of the receptor and the 
G protein heterotrimer is schematically represented as a ribbon, with the receptor shown with a spectrum of colors 
that ranges from red at the N-terminal to purple at the C-terminal; the α, β, and γ subunits of the G protein are in gray, 
blue, and pink, respectively. The cytosolic ends of TM 5 and TM 6 and intracellular loop (IL) 3, which connects them, 
are indicated by labels. The blue arrows show directions of the β-sheet domains of the β subunit of the G protein.
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affected by the mutations, are on the cytosolic 
side of the receptor (Fig. 5C). The E308 residue 
is located in the long intracellular loop 3, which 
connects transmembrane domains 5 and 6.
Overexpression of the p.E308D and p.A397K 
mutants, but not of nonmutant GPR101, signifi-
cantly increased cell proliferation and secretion 
of growth hormone in rat GH3 cells (Fig. 4D and 
4E). As in the construct containing the nonmu-
tant receptor, the two mutant constructs result-
ed in increased cAMP signaling in GH3 cells in 
an in vitro reporter assay, both at baseline and 
in the presence of 10 μM forskolin, a direct 
stimulator of adenylyl cyclase (Fig. 4F).
Discussion
Several lines of evidence support the identifica-
tion of a new pituitary gigantism syndrome in 
young children carrying microduplications on 
chromosome Xq26.3, a disorder that is probably 
caused by GPR101 overexpression. We propose that 
this syndrome be called X-linked acrogigantism 
(X-LAG). First, we did not find disruption of 
Xq26.3 in patients with later-onset gigantism 
(Table 1). Second, the finding that patients with 
other conditions had different duplications with-
in the same region narrowed our focus to the 
smallest region of overlap. A duplication encom-
passing CD40LG and ARHGEF6 but not RBMX and 
GPR101 occurred in a family with low birth 
weight, intellectual disability, and craniofacial 
abnormalities,16 which suggests that duplica-
tions with the exclusion of RBMX and GPR101 do 
not lead to gigantism. Third, short stature has 
been reported in several patients with deletions 
in this region, which suggests that the absence 
of these genes may lead to the opposite pheno-
type (Table S4 in the Supplementary Appen-
dix).16-18 Other investigators have described at 
least 15 additional patients with the same pheno-
type of early-onset growth who may be good 
candidates for a diagnosis of X-LAG (Table S3 in 
the Supplementary Appendix).
The breakpoint features of Xq26.3 duplica-
tions suggest that they were generated by means 
of a replication-based mechanism that under-
lies the genesis of other copy-number variants 
(CNVs) and the pathogenesis of other genomic 
disorders.19
The cytogenetic data narrowed the smallest 
region of overlap to a segment spanning 
CD40LG, ARHGEF6, RBMX, GPR101, one microRNA 
(miR-934), and a small nucleolar RNA (SNORD61) 
of unknown function. We did not detect CD40LG 
expression in the pituitary tissues from our pa-
tients (Fig. 4). Messenger RNA for ARHGEF6 and 
RBMX was expressed to a similar degree in af-
fected and unaffected tissues from duplication 
carriers. Of all the genes and the noncoding 
RNAs in the duplicated segment, only GPR101 
had markedly increased expression in the pitu-
itary tumors from the duplication carriers (Fig. 4).
GPR101 is an orphan G-protein–coupled recep-
tor that is strongly expressed in the hypothalamus 
in rodents (Fig. S11 and S12 in the Supplemen-
tary Appendix).13,14,20 It was recently shown that 
a fragment of the gonadotropin-releasing hor-
mone could be a ligand for this receptor.21 The 
GPR101 protein may also play a role in hypotha-
lamic control of energy homeostasis.22 The ef-
fect of a mutation (p.A397K) that is predicted to 
activate GPR101 when tested in vitro and in mice 
supports such a role.15 The pituitary-specific over-
expression of GPR101 may be due to a gene-dose 
effect (as described in many genomic disorders23) 
or to an unknown promoter sequence created by 
the chromosomal rearrangement, although we did 
not identify any putative new promoter, or to per-
turbed chromatin regulation due to the genomic 
structural alteration from duplication CNVs.24,25 
On the basis of our data from transfection experi-
ments, we cannot rule out a modest contribution 
of RBMX and ARHGEF6 coexpression to cell prolif-
eration. However, unlike GPR101, neither ARHGEF6 
nor RBMX was overexpressed in the pituitary 
tumors from children with microduplications.
Our studies of sporadic acromegaly provide 
further support for a role of GPR101 in X-LAG. 
We found a recurrent GPR101 mutation, p.E308D, 
in 4.4% of DNA in tumor samples and in 1.9% 
of DNA in PBMC samples obtained from patients 
with isolated acromegaly. In at least one patient, 
the mutation was present only in the tumor DNA. 
We did not identify GPR101 mutations in families 
with familial isolated pituitary adenomas. A model 
of human GPR101 in complex with a Gs hetero-
trimer showed that both the p.E308D mutation 
and the previously described p.A397K mutation15 
are on the cytosolic side of the receptor that 
interacts with heterotrimeric G proteins. Residue 
E308 is located in a remarkably long intracellu-
lar loop, which connects two transmembrane 
domains. But in the absence of a model template 
for the GPR101 intracellular loop in which E308 
resides, it is difficult to estimate the structural 
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effect of the p.E308D substitution. However, trans-
fection of a construct expressing GPR101 contain-
ing the p.E308D mutation increased proliferation 
and growth hormone secretion in a rat pituitary 
cell line. Moreover, we showed that GPR101 can 
strongly activate the cAMP pathway, for which the 
mitogenic effects in pituitary somatotropes are 
well established.26 These data further support a 
role for variant GPR101 in sporadic acromegaly.
The mechanism by which mutant GPR101 
contributes to increased growth hormone secre-
tion is unclear. Some of the patients with early-
onset gigantism whom we evaluated had normal 
or mildly elevated levels of circulating growth 
hormone–releasing hormone (but below the 
threshold required for ectopic tumoral secretion 
of this hormone), as was previously noted in 
Family F1.8 The tumor tissue showed strong 
expression of the growth hormone–releasing 
hormone receptor, in contrast to its expression 
of growth hormone–releasing hormone, which 
was low or absent (Fig. S15 in the Supplemen-
tary Appendix).
In conclusion, our results suggest that Xq26.3 
microduplication is associated with a clinical 
syndrome of early-onset gigantism, which we 
have termed X-LAG. An increased dose of GPR101 
on chromosome Xq26.3 probably causes the dis-
ease, and its activation by mutation occurs in 
patients with sporadic acromegaly. Xq26.3 micro-
duplications may explain other historical cases 
of gigantism with features that closely resemble 
those of X-LAG.27,28 Our results offer an oppor-
tunity to study a new pathway involved in the 
central regulation of human growth.
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